BLTE BELITE BIO, INC

Nasdaq belitebio.com


$ 111.08 $ -1.32 (-1.17 %)    

Tuesday, 04-Nov-2025 15:59:53 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 111.08
$ 111.19
$ 99.00 x 1,500
$ 129.22 x 100
-- - --
$ 49.00 - $ 116.24
145,844
na
3.54B
$ 0.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 benchmark-maintains-buy-on-belite-bio-raises-price-target-to-132

Benchmark analyst Bruce D. Jackson maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $80 to $132.

 belite-bio-says-center-for-drug-evaluation-of-chinas-nmpa-agrees-to-accept-nda-with-priority-review-for-tinlarebant-for-treatment-of-stargardt-disease-based-on-interim-analysis-results-from-phase-3-dragon-trial

NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025SAN DIEGO, Oct...

 hc-wainwright--co-maintains-buy-on-belite-bio-lowers-price-target-to-98

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and lowers the price target from $100 ...

 belite-bio-completes-last-subject-visit-in-phase-3-dragon-clinical-trial-evaluating-tinlarebant-for-treatment-of-stargardt-disease-type-1

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug...

 belite-bio-announces-125m-pipe-financing-at-64share-with-195m-shares-and-warrants-potential-additional-150m-at-7680share

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Sol...

 belite-bio-q2-eps-050-misses-040-estimate

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.40) ...

 belite-bios-earnings-outlook
Belite Bio's Earnings Outlook
08/08/2025 14:07:37

 hc-wainwright--co-reiterates-buy-on-belite-bio-maintains-100-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $100 price target.

 belite-bio-enrolls-500-subjects-globally-in-phoenix-trial-advancing-oral-tinlarebant-for-geographic-atrophy-in-dry-age-related-macular-degeneration

500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Aus...

 cantor-fitzgerald-reiterates-overweight-on-belite-bioto-overweight

Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:BLTE) from Overweight to Overweight.

 hc-wainwright--co-reiterates-buy-on-belite-bio-maintains-100-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $100 price target.

 belite-bio-q1-eps-045-misses-035-estimate

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.35) ...

 earnings-outlook-for-belite-bio
Earnings Outlook For Belite Bio
05/13/2025 15:02:11

 benchmark-reiterates-buy-on-belite-bio-maintains-80-price-target

Benchmark analyst Bruce Jackson reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $80 price target.

 belite-bio-analysts-see-potential-for-stock-gains-with-progress-in-key-trials

Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION